Editorial: Legal delays may be a plus for state's stem-cell effort
By San Jose Mercury News,
San Jose Mercury News
| 06. 01. 2006
The delays in implementing California's ambitious stem-cell initiative -- primarily the result of litigation that borders on being nuisance suits -- have been immensely irritating to those wanting to push forward with basic research.
But the delay has had the side benefit of allowing the stem-cell agency to solidify its planning, structure and regulations. That in turn enhances the chances that when research dollars start flowing at the rate of nearly $300 million a year, the state will have a program in place that delivers on its ambitious promises.
Once rid of legal challenges to Proposition 71, hopefully by next spring, California can start to dole out in a single year more than the National Institutes of Health have granted for stem-cell research in this decade. So far, only a trickle of the promised $3 billion in bonds has flowed from the state to scientists.
The delays also give the state time to resolve its remaining legislative oversight issues. State Sen. Deborah Ortiz, D-Sacramento, took a big step in that direction when she wisely agreed to withdraw a bill that...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...